Erasca, Inc. (ERAS)

Erasca's stock has experienced significant movement in the past six months, with a return of +503.5%. In February 2026, the stock rose 6.4% and hit a 52-week high. In January 2026, several investment banks updated their ratings and price targets for Erasca, and the company completed an upsized public offering. In December 2025, Erasca reported its cash, cash equivalents, and marketable securities balance, which is expected to fund operations into the second half of 2028. In June 2025, the FDA cleared an Investigational New Drug (IND) application for ERAS-4001. In May 2025, Erasca announced the FDA clearance of an IND application for ERAS-0015 and the submission of an IND application for ERAS-4001, and made a strategic decision to pursue partnership opportunities for naporafenib. In March 2025, Erasca reported a net loss for the full year ended December 31, 2024. In May 2024, Erasca announced a layoff of 18% of its employees and acquired worldwide rights to ERAS-4001 and ex-China rights to ERAS-0015.

Given that Erasca, Inc. is a clinical-stage precision oncology company focused on developing therapies for cancer, the demand for its future products is primarily driven by the prevalence and incidence of RAS/MAPK pathway-driven cancers, which is generally not subject to seasonal fluctuations. Therefore, there is no indication of demand seasonality for Erasca, Inc.'s products or services at its current stage of development.

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with cancers driven by the RAS/MAPK pathway. The company's pipeline targets key upstream and downstream signaling nodes in the RAS/MAPK pathway, directly targeting RAS, and addressing escape routes that emerge during treatment. Major products and pipeline candidates include Naporafenib, ERAS-007, ERAS-601, ERAS-0015, and ERAS-4001.

Erasca, Inc. is headquartered in San Diego, California, and maintains an office in San Francisco. The company emphasizes environmental initiatives, with its San Diego office being Gold LEED certified and its San Francisco office Platinum LEED certified. While the company is a clinical-stage entity, its mission to address RAS/MAPK pathway-driven cancers globally implies a worldwide focus for its potential therapies.

Erasca has cultivated a reputation as a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers. The company is recognized for assembling one of the deepest RAS/MAPK pathway-focused pipelines in the biotechnology sector. Events that have positively impacted its reputation include successful public offerings and private placements, clearance of Investigational New Drug (IND) applications for key pipeline candidates, and positive analyst sentiment.

The ownership structure of Erasca (ERAS) stock is a combination of institutional, retail, and individual investors. Approximately 19.86% of the company's stock is owned by Institutional Investors, 12.38% by Insiders, and 67.76% by Public Companies and Individual Investors. Major institutional owners include Frazier Life Sciences Management, L.P., T. Rowe Price Investment Management, Inc., VR Adviser, LLC, Logos Global Management LP, BlackRock, Inc., Suvretta Capital Management, Llc, Paradigm Biocapital Advisors LP, Vanguard Group Inc, Arch Venture Corp and Vivo Capital, LLC. A significant individual owner is Jonathan Lim, the Chairman and CEO, who holds 11.4% of the equities.